Brought to you by 
AstraZeneca buys MedImmune for $15.6bn
Apr 2007
Executive Summary
AstraZeneca PLC has found its first entry into the vaccines market through the acquisition of MedImmune. AZ offered $58 per share for the company, a 60% premium to MedImmune's market average 10 days prior to its initial announcement in early April that it was searching for a buyer. The deal is valued at about $15.6bn.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys MedImmune for $15.6bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice